- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05406531
The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors
The Effectiveness of Mobile-based Psychological Interventions in Reducing Psychological Distress and Preventing Stress-related Changes in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors- Randomized Controlled Trial
Study Overview
Status
Conditions
Detailed Description
Background:
Most studies focusing on the effects of psychological interventions on health-related outcomes have relied on self-reports. There is also growing research interest in the effects of such interventions on directly measurable biological processes associated with chronic stress. Neuroendocrine-immune system interactions are fundamental tools through which stress affects the course of cancer. The study will examine effect of three psychological interventions on most frequently studied stress related biomarkers: cortisol, HRV (heart- rate variability), CRP, relative and absolute counts of: B-lymphocytes ,T-lymphocytes, NK-cells, NK-T-like cells, monocytes; cytokine levels. Although current research suggests salutogenic changes in the immune profile of cancer patients as a result of psychological interventions, the results of individual studies are still inconsistent. To get clearer outcomes researchers decided to follow recommendations for researchers in manner that optimizes study design: to recruit very homogenous sample of cancer patients, to continue measurements in 3 and 9 months follow up, to collect data on individual´s adherence to protocol of mobile application.1,2 In addition to biomarkers, researchers will monitor changes in psychological variables.
Aims of the project and main hypotheses:
- To test the long-term and short-term effectiveness of eHealth adaptations of three standardized mental health support programmes for cancer patients (MBCT-Ca, PP and AT) - administered through the mobile application MOÚ MindCare, in reducing psychological distress and preventing changes in the functioning of the autonomic nervous system, endocrine system and immune system that have been linked to chronic stress and are likely to have a negative impact on both mental and physical health in the long-term perspective if not managed. The investigators expect that participants in all three intervention group will show more adaptive psychological functioning, higher quality of life, lower levels of stress, depression, anxiety, fatigue, sleep disturbances and other common problems associated with breast cancer survivorship, higher HRV levels and lower cortisol levels as compared to the treatment-as-usual control group, when controlling for pre-intervention values. The investigators also expect group differences in immune system functioning, correlated with differences in other markers of stress.
- To compare the potentially differential effects of the three intervention programmes on biological and psychological indicators of stress and quality of life. The investigators tentatively expect programmes involving a cognitive component (MBCT-Ca and PP) to be more effective than AT, especially for psychological outcomes.
- To examine the extent to which the observed effects of each programme are mediated by characteristics the interventions are primarily expected to influence. The investigators expect the effect of MBCT to be primarily mediated by mindfulness, self-compassion and emotion regulation, and the effect of PP to be primarily mediated by self-compassion, gratitude and perceived hope.
- To evaluate the moderating roles of intervention adherence and perceived acceptability in the effectiveness of the intervention programmes. The investigators expect higher adherence and acceptability to be associated with greater improvement in the outcome variables. These data will also help identify types of individuals for whom each programme might be most and least suitable and provide information on sources of potential problems with MOÚ MindCare - or generally mHealth - intervention adherence.
Methods:
The research is conceptualized as a randomized control trial employing a 4 × 4 factorial design. Participants will be randomly assigned to one of the four arms: 1. MBCT-Ca (Mindfulness Based Cognitive Therapy for Cancer) 2. PP (Positive Psychology) 3. AT (Autogenic training) 4.WL (Waiting list). Participants will take the 8 week online program via mobile application. Assessment measurements will be collected in four phases. Phase 1: Assessment at the start of the programme. Phase 2: Assessment in the week after programme completion. Phase 3: Follow-up assessment 3 months after the end of programme. Phase 4: Follow-up assessment 9 months after the end of programme. Data collection will contained: collection of blood samples, single lead ECG, administration of self-report measures. Main data collection points will be synchronized with regular check-ups for each participant to minimize drop-out rates and the burden on the participants.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miroslav Světlák, PhD.
- Phone Number: +420 549 49 1372
- Email: msvetlak@med.muni.cz
Study Contact Backup
- Name: Jana Halámková, PhD.
- Phone Number: +420 549 49 3759
- Email: jana.halamkova@mou.cz
Study Locations
-
-
Bohunice
-
Brno, Bohunice, Czechia, 62500
- Recruiting
- Faculty of Medicine, Masaryk University
-
Contact:
- Mirek Světlák, PhD.
- Phone Number: 549491372
- Email: msvetlak@med.muni.cz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women over the age of 18
- Breast cancer patients at the end of adjuvant treatment
Exclusion Criteria:
- Patients without a mobil device ("smart" mobile phone)
- Patients without internet access
- Patients with diagnosed: psychotic disorder; severe depressive episode; panic disorder; bipolar disorder; personality disorder associated with uncontrollable mood swings; PTSD; suicidal attempts and active suicidal ideation; disability pension due to non-specific mental or somatic problems; hospitalization due to a psychiatric disorder in the past year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online
MBCT-Ca uses cognitive behavioral therapy (CBT) methods in collaboration with mindfulness meditative practices and similar psychological strategies.
|
This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
|
Experimental: Positive Psychology - online
Positive psychology is focused on the character strengths and behaviors that allow individuals to build a life of meaning and purpose.
|
This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
|
Experimental: Autogenic Training - online
Autogenic training is a relaxation technique focusing on promoting feelings of calm and relaxation to help reduce stress and anxieties.
|
This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
|
No Intervention: Waiting list
No intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in heart rate variability (HRV) using ECG
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
HRV will be obtained from ECG measured according to a protocol involving a standardized sequence of measurements taken at rest with uncontrolled and controlled breathing.
The completion of questionnaire related to rumination and impact of the cancer event before the measurement of rest ECG will serve as the priming of distress.
The obtained data will be processed using the Kubios HRV Premium program- time-domain HRV parameters - RMSSD, SDNN, pNN50 and Power Spectrum density HRV parameters - LF power, HF power, and LF/HF ratio.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in symptoms of individual stress level using the Perceived Stress Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Perceived Stress Scale (PSS) is a classic stress assessment instrument.
The questions in this scale ask about feelings and thoughts during the last month.
Each question has five response options ranging in value from null to four (0=never; 1=almost never; 2=sometimes; 3=fairly often; 4=very often).
To find the total raw score, sum the values of the response to each question (reverse code items 4, 5, 7a and 8).
Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in depression, anxiety and stres using the Depression, Anxiety and Stress Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Depression, Anxiety and Stress Scale (DASS-21) is a 21 items scale designed to measure depression, anxiety, and stress.
The instrument comprises three subscales: the emotional states of depression, anxiety, and stress.
Each question has four response options ranging in value from null to four (0= did not apply to me at all; 1= applied to me to some degree, or some of the time; 2= applied to me a considerable degree or a good part of time; 3= applied to me very much or most of the time).
To find the total raw score, sum the values of the response to each question for each of subscale (scores will need to be multiplied by 2 to calculate the final score).
The lowest possible raw score is 0 and the highest possible raw score is 42 for each subscale.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in positive mental health using the Positive Mental Health Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Positive Mental Health Scale (PMHS) is a nine-item scale designed to measure positive mental health (combination of emotional, psychological, and social aspects of well-being).
Each item on the questionnaire is scored from 0 (do not agree) - 3 (agree).
The lowest possible raw score is 0 and the highest possible raw score is 27.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in health-related quality of life using The Functional Assessment of Chronic Illness Therapy (FACIT)-Spiritual Well-Being (Sp)
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT)-(Sp) is composed of the FACT-General (FACT-G) and a 12-item Spiritual Well-Being scale (FACIT-Sp-12).The FACT-G (Version 4) is a 27-item compilation of general questions divided into four primary QOL subscales: Physical Well-Being (PWB; 7-items), Social/Family Well-Being (SWB; 7-items), Emotional Well-Being (EWB; 6-items), and Functional Well-Being (FWB; 7-items).Each question has five response options ranging in value from null to four (0= not at all; 1= a little bit; 2=somewhat; 3= quite a bit; 4=very much).
The total FACT-G score is obtained by summing individual subscale scores (PWB + EWB + SWB + FWB).
The lowest possible raw score is 0 and the highest possible raw score is 48 in Spiritual Well-Being subscales.
The lowest possible raw score is 0 and the highest possible raw score is 108 in FACT-G.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in relative and absolute counts of B-lymphocytes (CD19+), T-lymphocytes, T-helper lymphocytes (CD3+ CD4+), T-cytotoxic lymphocytes (CD3+ CD8+), NK-cells (CD16+ CD56+), NK-T-like cells (CD3+ CD56+) and monocytes (CD14+)
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The counts will be obtained by flow cytometric immunophenotyping.
For immunophenotyping tests will be collected peripheral blood sample (2,6 ml of K3EDTA-blood) of patients.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in cytokine levels
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Cytokine levels (IL-1β, IL-2, IL-6, IL-8, IL-12, IFN-γ, TNFα, IL-17, IL-1ra, IL-4, IL-5, IL-10, TGF-β) will be analysed using the Bioplex 200 multiplex system.
For cytokines levels will be collected peripheral blood sample (7,5 ml of blood without anti-coagulants for serum separation).
Units of measurement: pg/ml (ng/l).
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in serum cortisol level
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Serum cortisol level will be determined by chemiluminescence-based immunoassay using the Cobas e 601 analyser (ROCHE Diagnostics).
For serum cortisol level will be collected peripheral blood sample (7,5 ml of blood without anti-coagulants for serum separation ) between 9-11.
a.m.
Units of measurement: nmol / l.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in levels of C-reactive protein (CRP)
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Levels of C-reactive protein (CRP) will be determined through the turbidimetric method automated on the Cobas c 501 module .
For CRP level will be collected peripheral blood sample (7,5 ml of blood without anti-coagulants for serum separation).Units of measurement: mg/l.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in current emotional state using the Self-Assessment Manikin
Time Frame: every single morning during a whole 8 weeks of intervention; every single afternoon during a whole 8 weeks of intervention; every single evening during a whole 8 weeks of intervention
|
Current emotional state will be assessed three times per day using three short items (Self-Assessment Manikin) directly incorporated in the MOÚ MindCare Application.
The Self-Assessment Manikin (SAM) measures pleasure, arousal, and dominance.
It is a non-verbal pictorial assessment technique.
|
every single morning during a whole 8 weeks of intervention; every single afternoon during a whole 8 weeks of intervention; every single evening during a whole 8 weeks of intervention
|
Adherence to/satisfaction with the MOÚ MindCare application and intervention programme using the MOÚ MindCare Feasibility Questionnaire
Time Frame: week 9 from baseline
|
Mobile application will be monitoring completing tasks by participants.
Satisfaction with the MOÚ MindCare application will be measured by the MOÚ MindCare Feasibility Questionnaire.
Questions have two, three, four or five response options ranging in value from one to two, three, four or five.
A few questions have open answers options.
To find the total raw score, sum the values of the response to each question (reverse code item: 4).
The lowest possible raw score is 8 and the highest possible raw score is 26.
A higher score represents more of the concept being measured.
|
week 9 from baseline
|
Change in emotion dysregulation using the Difficulties in Emotion Regulation Scale-SF
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Difficulties in Emotion Regulation Scale Short Form (DERS-SF) is a measure used to identify emotional regulation issues.
The measure covers 4 dimensions of emotional regulation: awareness and understanding of emotions; acceptance of emotions; the ability to engage in goal-directed behaviour and refrain from impulsive behaviour when experiencing negative emotions; and access to emotion regulation strategies perceived as effective.
Each question has five response options ranging in value from one to five (1=almost never; 2=sometimes; 3=about half of the time; 4=most of the time; 5=almost always).
The lowest possible raw score is 18 and the highest possible raw score is 90.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Changes in transdiagnostic and transtheoretical indicators of positive and adaptive functioning using the Five Facet Mindfulness Questionnaire-15
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The 15-item FFMQ (FFMQ-15) measures five facets: Observing, Describing, Acting with Awareness, Non-Judging of inner experience, and Nonreactivity to inner experience.
Each question has five response options ranging in value from one to five (1=never or very rarely true; 2= rarely true; 3=sometimes true; 4=often true; 5=very often or always true).
To find the total raw score, sum the values of the response to each question (reverse code items 3, 4, 7, 8, 9, 13 and 14).
The lowest possible raw score is 15 and the highest possible raw score is 75.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Changes in transdiagnostic and transtheoretical indicators of positive and adaptive functioning using the Applied Mindfulness Process Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Applied Mindfulness Process Scale (AMPS) measures the application of mindfulness practices in daily life among persons participating in mindfulness-based interventions.
The measure covers three domains of applied mindfulness processes: decentering, positive emotional regulation, and negative emotional regulation.
Each question has five response options ranging in value from null to four (0= never; 1= rarely; 2=sometimes; 3=often; 4=almost always).
To find the total raw score, sum the values of the response to each question.
The lowest possible raw score is 0 and the highest possible raw score is 60.
A score ranging from 0-20 is obtained by summing each factor individually.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Changes in transdiagnostic and transtheoretical indicators of positive and adaptive functioning using the Self- Compassion Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Self-compassion Scale (SCS) is a psychometrically measurement of self-compassion.
The instrument comprises six subscales: Self-Kindness; Self-Judgment; Common Humanity; Isolation; Mindfulness and Over-identification.
Each item on the questionnaire is scored from 1-5 (1=almost never, 5=almost always).
To find the total raw score, sum the values of the response to each question for each of subscale (reverse code items 1, 2, 4, 6, 8, 13, 16, 18, 20, 21, 24 and 25).
The lowest possible raw score is 26 and the highest possible raw score is 130.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Changes in transdiagnostic and transtheoretical indicators of positive and adaptive functioning using the Gratitude Questionnaire Six-Item Form
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Gratitude Questionnaire-Six-Item Form (GQ-6) is a self-report questionnaire measures individual differences in the proneness to experience gratitude in daily life.
Each question has seven response options ranging in value from one to seven (1= strongly disagree; 2= disagree; 3= slightly disagree; 4= neutral; 5= slightly agree; 6= agree; 7= strongly agree).
To find the total raw score, sum the values of the response to each question (reverse code items 3 and 6).
The- Page 4 of 7 - lowest possible raw score is 6 and the highest possible raw score is 42.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in transdiagnostic and transtheoretical indicators of positive and adaptive functioning using the Perceived Hope Scale
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Perceived Hope Scale (PHS) is self-report questionnaire measures individual judgment about one's experience and levels of hope.
Each item on the questionnaire is scored from 0-5 (0= strongly disagree, 5= strongly agree).
To find the total raw score, sum the values of the response to each question.
The lowest possible raw score is 0 and the highest possible raw score is 30.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Basic personality traits using the Big Five Inventory BFI-10
Time Frame: baseline
|
The Big Five Inventory-10 (BFI-10) measures the Big Five personality traits: Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
Each question has five response options ranging in value from one to five (1= disagree strongly; 2= disagree a little; 3= neither agree or disagree; 4= agree a little; 5= agree strongly).
To find the total raw score, sum the values of the response to each question for each of subscale (reverse code items 1,3,4,5 and 7).
The lowest possible raw score is 10 and the highest possible raw score is 50.
A score ranging from 2-10 is obtained by summing each factor individually.
A higher score represents more of the concept being measured.
|
baseline
|
Change in rumination and reflection using the Rumination-Reflection Questionnaire
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Rumination Reflection Questionnaire (RRQ) measures an adaptive (self-focus) and maladaptive form (self- rumination) of self-focus or self-attention.
The instrument comprises two subscales: Rumination and Reflection.
Each question has five response options ranging in value from one to five (1= strongly disagree; 2= disagree; 3= neutral; 4= agree; 5= strongly agree).
To find the total raw score, sum the values of the response to each question for each of subscale (reverse code items 6, 9, 10, 13, 14, 17, 20 and 24).
The lowest possible raw score is 24 and the highest possible raw score is 120.
A score ranging from 12-60 is obtained by summing each factor individually.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in impact of event using the Impact of Event Scale-Revised
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Impact of Event Scale - Revised (IES-R) measures impact of recent and specific events, and post-traumatic stress disorder symptoms.
The instrument comprises three subscales: Intrusion; Avoidance and Hyperarousal.
Each question has five response options ranging in value from null to four (0= not at all; 1= a little bit; 2= moderately; 3= quite a bit; 5= extremely).
To find the total raw score, sum the values of the response to each question.
The lowest possible raw score is 0 and the highest possible raw score is 88.
A scores ranging from: 0-32; 0-32 and 0-24 are obtained by summing each factor individually.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in sleep quality using the Pittsburgh Sleep Quality Index
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Pittsburgh Sleep Quality Index (PSQI) measures sleep quality and disturbances.
The instrument comprises seven subscales: subjective sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep disturbances; use of sleeping medication and daytime dysfunction.
Questions have four response options ranging in value from null to three and a few questions with open answers options.
To find the total raw score, sum the values of the response to each question and for each subscale separately.
The sum of scores for components yields one global score.
The lowest possible raw score is 0 and the highest possible raw score is 21.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in fatigue using the Fatigue Symptom Inventory
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Fatigue Symptom Inventory (FSI) measures multiple aspects of fatigue, including its perceived severity, frequency, and interference with daily functioning.
Each item on the questionnaire is scored from 0-10 (0= not at all fatigued, 10= as fatigued as I could be).
To find the total raw score, sum the values of the response to each question.
The lowest possible raw score is 0 and the highest possible raw score is 130.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The total amount of received health care using the medical documentation software (GreyFox)
Time Frame: month 9 post-intervention
|
Number of PET, CT and MR imaging examinations, number of acute hospitalizations, the total cost of care, and the type and amount of anticancer treatment will be measured by using hospital database program called "GreyFox".
|
month 9 post-intervention
|
Changes in severity of somatic symptoms using the Patient Health Questionnaire 15
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Patient Health Questionnaire (PHQ-15) measures common mental disorders and is used to assess somatic symptom severity and screen for the potential somatisation and somatoform disorders.
Each question has three response options ranging in value from null to two (0= not bothered at all; 1= bothered a little; 2= bothered a lot).
To find the total raw score, sum the values of the response to each question.
The lowest possible raw score is 0 and the highest possible raw score is 30.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in pain medication use
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The following variables about medication will be collected: name and strength of medication; number of days in the week the medication was taken (0-7), number of taken doses per the day (0-7 and more); regularity of a medication using (options: regularly/according to need).
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in psychiatric medication use
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The following variables about medication will be collected: name and strength of medication; condition the medication is used for (options= sleep disorder/anxiety/depression/other); number of days in the week the medication was taken (0-7); number of taken doses per the day (0-7 and more); regularity of a medication using (options: regularly/according to need).
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in pain intensity using the Numerical Rating Scale of Pain Intensity
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Pain intensity will be measured by the Numerical Rating Scale of Pain Intensity (NRS-I) consists of a range of numbers (0-10).
The lowest number is null and represents "no pain".
The highest number is ten and represents "an extreme level of pain".
Respondents are asked to choose the number that best represents a level of pain intensity.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Change in dealing with pain using the Pain Self-Efficacy Questionnaire
Time Frame: baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
The Pain Self-Efficacy Questionnaire is a 10-item scale designed to measure the confidence of people with ongoing pain to achieve different activities despite pain.
Each item on the questionnaire is scored from 0 (not at all confident) to 6 (completely confident).
The lowest possible raw score is 0 and the highest possible raw score is 60.
A higher score represents more of the concept being measured.
|
baseline, week 9 from baseline, month 3 post-intervention, month 9 post-intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Socio-demographic variables
Time Frame: baseline
|
The following socio-demographic variables will be collected: gender, age, level of education, marital status, number of children (if any), employment status, any previous experience with autogenic training, psychotherapy, meditation, or another practice of self-development (how long/ how often is one practicing such activities).
|
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Miroslav Světlák, PhD., Masaryk University
Publications and helpful links
General Publications
- Sanada K, Alda Diez M, Salas Valero M, Perez-Yus MC, Demarzo MM, Montero-Marin J, Garcia-Toro M, Garcia-Campayo J. Effects of mindfulness-based interventions on biomarkers in healthy and cancer populations: a systematic review. BMC Complement Altern Med. 2017 Feb 23;17(1):125. doi: 10.1186/s12906-017-1638-y.
- Black DS, Slavich GM. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci. 2016 Jun;1373(1):13-24. doi: 10.1111/nyas.12998. Epub 2016 Jan 21.
- Heiss S, Vaschillo B, Vaschillo EG, Timko CA, Hormes JM. Heart rate variability as a biobehavioral marker of diverse psychopathologies: A review and argument for an "ideal range". Neurosci Biobehav Rev. 2021 Feb;121:144-155. doi: 10.1016/j.neubiorev.2020.12.004. Epub 2020 Dec 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AZV2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Stage I
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingGynecologic Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage III Breast Cancer | Stage III Gynecologic Cancer | Stage III Colorectal Cancer | Stage I Colorectal Cancer | Stage II Colorectal Cancer | Stage I Gynecologic... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
City of Hope Medical CenterTerminatedStage I Breast Cancer | Cancer Survivor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesCompletedStage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Thompson Cancer Survival CenterRecruitingBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
-
Dana-Farber Cancer InstituteCompletedEarly Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Dana-Farber Cancer InstituteCURE FoundationCompletedBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage IIIUnited States
Clinical Trials on Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruiting
-
Florida State UniversityCompletedPain, Postoperative | Chronic Pain | Pain, Acute | Pain CatastrophizingUnited States
-
University of Colorado, BoulderUniversity of Toronto; Children's Hospital Medical Center, Cincinnati; University... and other collaboratorsCompleted
-
University Medical Center GroningenUniversity of GroningenCompleted
-
Lady Davis InstituteDouglas Mental Health University InstituteRecruitingOlder Age; DepressionCanada
-
Vanderbilt University Medical CenterActive, not recruiting
-
Radboud University Medical CenterFonds Psychische GezondheidCompleted
-
University of California, San FranciscoMount Zion Health FundCompletedDepression | Parkinson Disease | AnxietyUnited States
-
University of AberdeenNHS Greater Glasgow and Clyde; NHS Grampian; University of GlasgowCompletedDepression | Diabetes | AnxietyUnited Kingdom
-
University of North Carolina, Chapel HillPatient-Centered Outcomes Research Institute; Augusta University; University...RecruitingDepression | Anxiety | Autism Spectrum DisorderUnited States